Breaking News


Efficacy and safety of infliximab in psoriasis patients previously treated with etanercept: Interim results


An open-label trial enrolled 210 patients with plaque psoriasis to treatment with infliximab after they had failed to respond to etanercept with or without methotrexate or ciclosporin. Infliximab (5 mg/kg) was administered at weeks 0, 2 and 6, 2 weeks after the last dose of etanercept. A safety assessment was conducted at week 10. Results are presented for the first 105 patients. The primary endpoint was the percentage of patients who received at least one dose of infliximab and had a Physicians Global Assessment (PGA) score of 1 or less at week 10. Over half (64.4%) of patients had a response at week 10. The majority of patients had a ...

to Continue Reading, Login Now

Please Login

If you are a registered user but you have forgotten your password, please click here
If you are not a registered user, please register here

return to breaking news list